ChinaDaily Briefs

Daily Brief China: Shanghai Friendess Electronic, Great Wall Motor, Kunlun Energy, KE Holdings , SHEIN, Aier Eye Hospital Group, 21Vianet Group and more

In today’s briefing:

  • China ETFs: Inflows Continue to Support the Market
  • Quiddity A/H Premium Weekly (Sep 1): China Life, Wide Premia Industrials, Banks Starting To Move
  • Kunlun Energy (135 HK): The Story Is Still Going On
  • [KE (BEKE US, BUY, TP US$24) TP Change]: Silver Lining Appear in Industry Cycle, Maintain BUY
  • Why Is SHEIN Getting Into Bed with Forever 21? | Plus, More Legal and Political Challenges in US
  • Aier Eye Hospital Group (300015.CH) 23H1 – Time to Face the Gap Between Ideal and Reality
  • Morning Views Asia: O-Net Technologies (Group)


China ETFs: Inflows Continue to Support the Market

By Brian Freitas

  • Money continues to flow into mainland China ETFs taking the total inflows since 18 July to over US$25bn. This has likely helped stabilise the market and prevent a bigger fall.
  • The inflows continue to be largest on ETFs tracking headline indices – CSI 300, STAR50, CSI1000, CSI 500, SSE50, ChiNext. Plus there are inflows on some sectoral and thematic ETFs.
  • The skew between stocks gaining 20%+ over the period vs those dropping -20% or more has improved significantly over the last week.

Quiddity A/H Premium Weekly (Sep 1): China Life, Wide Premia Industrials, Banks Starting To Move

By Travis Lundy

  • The Brand-Spanking New (three weeks old) A-H Monitor has tables, charts, measures galore. 
  • Last week was slightly disappointing but the Recommendations Outperformed the universe.
  • New stimulus measures are partly supply side, and a little bit demand side, but they’re not big enough yet to move the needle. Mainland ETF buying smells like National Team.

Kunlun Energy (135 HK): The Story Is Still Going On

By Osbert Tang, CFA

  • We think Kunlun Energy (135 HK) will see its operating momentum accelerate in 2H23, leading by better natural gas sales growth and sustained positive dollar margin performance.
  • It has strengthened its financial position in 1H23, with net cash amounting to 36% of market cap. This has demonstrated its cash-generating capability and controlled capex. 
  • Its 7.0x and 6.6x PERs for FY23 and FY24 are inexpensive. Its annualised ROE of 10.6% is also attractive. There is room for the other businesses to recover in 2H23.

[KE (BEKE US, BUY, TP US$24) TP Change]: Silver Lining Appear in Industry Cycle, Maintain BUY

By Shawn Yang

  • KE Holdings (Beike) reported 2Q23 GTV 5.6% lower than our estimate, revenue (2.6%)/0.4% vs. our estimate/consensus, and non-GAAP NI 21.8%/42.9% higher than our estimate/consensus. 
  • We think 3Q23 is the trough and expect a rebound in 4Q23 as more substantial supportive policies laying out in China. 
  • We maintain the stock as BUY rating and raised TP by US$2 to US$24/ADS

Why Is SHEIN Getting Into Bed with Forever 21? | Plus, More Legal and Political Challenges in US

By Daniel Hellberg

  • In this insight we analyze the drivers of a new relationship between SHEIN and Forever 21
  • We think SHEIN agreed to the deal in part to become more “mainstream” in the US
  • We also believe SHEIN takes seriously the legal and political risks it faces ahead of US IPO

Aier Eye Hospital Group (300015.CH) 23H1 – Time to Face the Gap Between Ideal and Reality

By Xinyao (Criss) Wang

  • Aier’s revenue would be up 20%+ YoY in 2023, but one risk is the slowing growth rate of refractive/other consumption upgrading projects in the context of sluggish consumption in 23H2.
  • The positive impact of aging on performance would not be able to hedge against the negative impact of declining birth rate, ultimately leading to a decline in overall performance growth.
  • When Aier’s external expansion model fails and endogenous growth is lower-than-expectation, we suggest that Aier increase dividends/stock buybacks instead of ineffective expansion. This would make Aier more attractive to investors.

Morning Views Asia: O-Net Technologies (Group)

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars